Singapore markets close in 3 hours 51 minutes

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.5000-0.0800 (-1.75%)
At close: 04:00PM EDT
4.6000 +0.10 (+2.22%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.5800
Open4.6000
Bid4.4600 x 300
Ask4.5000 x 200
Day's range4.4900 - 4.7100
52-week range4.4500 - 9.0700
Volume2,956,572
Avg. volume3,097,704
Market cap927.675M
Beta (5Y monthly)1.93
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

    RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. “We are excited to announce that ORLADEYO is now approved in the region’s largest market, following the positive regulatory decisions w

  • GlobeNewswire

    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted six newly-hired employees stock options to purchase an aggregate of 43,975 shares, and restricted stock units (RSUs) covering an aggregate of 30,625 shares, of BioCryst common stock. The options and RSUs were granted as of March 29, 2024, as inducements material to each employee entering into employ

  • GlobeNewswire

    BioCryst to Present at Upcoming Investor Conferences

    RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024, at 2:30 p.m. ET and the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15 a.m. ET. Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media s